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Abstract
Background: Several predictors of clinical outcomes after percutaneous transluminal angioplasty 
(PTA) interventions in patients with peripheral arterial disease (PAD) have been investigated. Indices 
of endothelial function, arterial pulse waveform analysis (aPWA) and markers of peripheral artery 
ischemia were among the most commonly examined. The aim of the current study was to assess the re-
lationship between potential predictors of clinical outcomes after peripheral artery PTA during a 1-year 
follow-up period. 
Methods: The study included 72 individuals with PAD at a mean age of 66.3 ± 7.2 (79.1% males). All 
patients underwent PTA of the peripheral arteries. Among them, 42.8% presented critical limb ischemia 
(CLI). During the first visit and at 1 month and 6 months after PTA, endothelial function and aPWA 
measurements were taken. Ankle-brachial index (ABI), toe-brachial index (TBI) and physical evalu-
ation of the limbs took place during the first visit and at 1, 6 and 12 months after the PTA. The study 
endpoints included myocardial infarction, amputation, death, stroke and reintervention. All subjects 
included in the study were observed for 386 days after the PTA. 
Results: A significant improvement was noted in walking distance after PTA at the following time 
points, as well as transient improvement of ABI and flow-mediated dilatation (FMD) and no significant 
change in aPWA indices and reactive-hyperaemia index (RHI). The mean ABI, TBI, FMD and RHI 
values did not correlate with each other at baseline. There were 25 study endpoints which occurred in  
16 patients during the follow-up period (22.2%). Patients with CLI, hypercholesterolemia, lower dias-
tolic blood pressure, higher subendocardial viability ratio, a greater number of pack-years and lower 
TBI at baseline presented significantly poorer clinical outcomes in terms of endpoint events.
Conclusions: Endothelial function assessed as FMD and reactive hyperemia–peripheral arterial  
tonometry (RH-PAT) before PTA in patients with advanced PAD do not predict clinical outcomes during 
the 1-year follow-up. (Cardiol J 2020; 27, 2: 142–151)
Key words: endothelial function, percutaneous transluminal angioplasty, arterial pulse 
waveform analysis, clinical outcomes
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Introduction
The incidence of peripheral artery disease 
(PAD) increases are due to the aging population. 
Early diagnosis and adequate treatment could im-
prove clinical outcomes. Several tools have been 
proven to accurately indicate peripheral athero-
sclerosis, beginning with markers of endothelial 
dysfunction expressed as flow-mediated dilatation 
(FMD), reactive-hyperemia index (RHI) or arterial 
pulse-waveform analysis (aPWA) indices and end-
ing in clinically apparent lower limb atherosclerosis 
assessed by the ankle-brachial index (ABI) or 
toe-brachial index (TBI), finally proven by arte-
rial angiography or arterial computed tomography 
[1–5]. Nowadays, most patients with clinically 
symptomatic lower limb atherosclerosis are treated 
with percutaneous transluminal angioplasty (PTA). 
Likewise, predictors of clinical outcomes after 
PTA are of great interest to scientists. Improving 
the knowledge of predictors and their associated 
mechanisms may improve PTA outcomes. Among 
the proven prognostic factors that may influence 
PTA results we may find selected endothelial func-
tion and aPWA indices, as well as clinical comor-
bidities, clinical presentation of PAD estimated by 
the Rutherford scale or ABI and the angiographic 
image of culprit lesions [6–10].
The aim of the current study was to assess 
the relationships between aPWA, endothelial func-
tion indices and clinical outcomes in patients with 
PAD following PTA of lower limb arteries during 
a 1-year follow-up period. 
Methods
Study design
The study was conducted as a prospective, 
single-center follow-up evaluation, assessing the in-
fluence of initial endothelial function on the number 
of clinical cardiovascular events (death, myocardial 
infarction, stroke, amputation) and the number of 
reinterventions in patients with symptomatic PAD 
assessed during a 12 month follow up. Patients with 
critical limb ischemia (CLI) as well as those with 
stable PAD (Rutherford class 2 to 3) due to iliac, 
femoropopliteal or below the knee disease were 
eligible for the study.
 
Exclusion criteria were a his-
tory of end stage kidney disease, age above 85 and 
pain related to limb ischemia not allowing to obtain 
a horizontal position. Patients with incompressible 
tibial arteries were not eligible for the study.
All subjects provided written and informed 
consent before the study began. The study com-
plies with the Declaration of Helsinki and was 
approved by the local ethics committee. 
Endovascular procedures
Assessment before the intervention included 
clinical examination, calculation of the ABI, TBI, 
color duplex sonography and tonometry. Endovas-
cular treatment was performed in a routine manner. 
A 4 F to 6 F sheath was introduced into the artery 
and diagnostic angiography was performed. Each 
individual received 5000 IU of unfractionated 
heparin that was injected intra-arterially. The 
affected artery was treated using over the wire 
balloon catheters, and wherever necessary, nitinol 
self-expanding stents or cobalt-chromium balloon 
expandable stents were implanted. Post-inter-
ventional therapy lasted 4 weeks and consisted of 
both acetylsalicylic acid (75 mg/d) and clopidogrel 
(75 mg/d). High dose statins (atorvastatin 40 mg 
to 80 mg or rosuvastatin 20 mg to 40 mg) were 
initiated at the baseline assessment to all patients 
and maintained for life. Follow-up visits were done 
1, 6 and 12 months after the intervention. Success-
ful angioplasty was defined by a final angiogram 
with residual stenosis of 30% or less and post-
interventional ABI improvement of at least 0.1.
Endothelial function tests
FMD
The study was performed on the basis of 
current FMD assessment guidelines [11]. The 
study was performed between 8 and 10 a.m. in 
a temperature-controlled room (20° to 22°C) with 
subjects resting in a supine position. Brachial 
diameter was imaged using a high-resolution 
(14-MHz line array) transducer ultrasound system 
(Siemens, Erlangen, Germany) equipped with 
electronic callipers, vascular software for two-
dimensional imaging, color and spectral Doppler, 
and an internal electrocardiogram. The brachial 
artery was imaged at a location 2–5 cm above 
the cubital fossa. A sphygmomanometer cuff 
was placed on the forearm. The cuff was inflated 
at least 50 mmHg above systolic pressure to 
occlude artery inflow for 5 min. All vasodilation 
measurements were made from 60 to 90 s after 
deflation. Measurements were performed on 
a personal computer using brachial reactivity 
analysis software (Siemens). The response of 
the vessel diameter to reactive hyperemia was 
calculated and expressed as a percentage change 
relative to the diameter immediately before cuff 
inflation.
144 www.cardiologyjournal.org
Cardiology Journal 2020, Vol. 27, No. 2
RHI
Digital pulse amplitude was measured in 
a standardized setting (i.e., a quiet, dark, temper-
ate environment [21 to 24°C]) with a Peripheral 
Arterial Tone (PAT) device that comprises a pneu-
matic plethysmograph measuring digital pulse 
volume changes (Endo-PAT2000, Itamar Medical, 
Caesarea, Israel). Patients were in a fasting state.
The digital pulse amplitude was acquired 
continually during the examination and digital-
ly recorded to a laptop. Data was analyzed by 
a computerized algorithm (Itamar Medical), which 
automatically and operator-independently calcu-
lates RHI.
The assessment of the extent  
of lower limb ischemia 
The ABI was calculated with the patient in 
a supine position. The highest systolic pressure of 
the anterior or posterior tibial artery was measured 
in each limb and was divided by the highest bra-
chial artery pressure. The mean ABI value of the 
two legs were included in statistical analysis. The 
TBI was calculated with the patient supine. The 
systolic pressure on the big toe was obtained using 
a photoplethysmograph (Nicolet VasoGuard; VIASYS 
Healthcare, Madison, WI, USA) in each limb and 
was divided by the highest brachial artery pressure.
IMT
To measure carotid intima–media thickness 
(IMT), ultrasonography of the common carotid 
artery, carotid bifurcation, and internal carotid 
artery of the left and right carotid arteries was 
performed with a 7.5-MHz linear-array transducer 
(Siemens, Erlangen, Germany). On a longitudinal, 
two-dimensional ultrasound image of the carotid 
artery, the anterior and posterior walls of the ca-
rotid artery are displayed as two bright white lines 
separated by a hypoechogenic space. The distance 
between the leading edge of the first bright line of 
the far wall (lumen-intima interface) and the lead-
ing edge of the second bright line (media-adventitia 
interface) indicates the IMT.
aPWA analysis
Arterial pulse waveform analysis assessment 
of arterial stiffness was performed non-invasively 
with the commercially available SphygmoCor 
system (AtCor Medical). Peripheral pressure 
waveforms were recorded from the radial artery 
at the wrist, using applanation tonometry with 
a high-fidelity micromanometer. After 20 sequential 
waveforms had been acquired, a validated gener-
alized transfer function was used to generate the 
corresponding central aortic pressure waveform. 
Aortic pressure was the maximum systolic pres-
sure minus pressure at the inflection point. Pulse 
pressure was measured (PP), also augmentation 
index (AI), central augmentation index (CAI), ejec-
tion duration (ED), subendocardial viability ratio 
(SEVR), central augmentation pressure (CAP), 
central augmentation pressure normalized for 
a heart rate of 75 bpm (CAP-HR75), stiffness index 
(SI) and reflection index (RI) were measured [12].
Statistical analysis
The data are expressed as means, standard 
deviation, medians and interquartile range (IQR) 
when appropriate. The test choice depended on 
the distribution of particular data. To compare 
measurable variables (or to assess the statis-
tical significance of the observed differences), 
parametric tests were used: the two-sided Student 
t test and Spearman linear correlation. In case of 
missing mentioned assumptions, non-parametric 
tests were used (Friedman ANOVA, Mann-Whitney 
U-Test, Wilcoxon signed-rank and c2). A p-value of 
< 0.05 was considered significant. STATISTICA 
for Windows Release 10 (StatSoft Inc., 2011) was 
used for data analysis.
Results
General characteristics 
Clinical characteristics, family history and 
pharmacological therapy of patients included into 
the present study are demonstrated in Table 1, 
whereas culprit artery characterization is pre-
sented in Table 2. 
Clinical outcomes 
The pain-free walking distance (PFWD) and 
maximal walking distance (MWD) increased signifi-
cantly after PTA during 6 months of the follow-up 
period (p = 0.04 and p = 0.02, respectively; Table 3). 
The improvement of MWD after 6 months of follow-
up was significantly poorer in patients with kidney 
failure (p = 0.01). Neither the PFWD change nor 
the MWD change during the follow up period was 
related to baseline indices of endothelial function, 
clinical picture of PAD and pulse waveform indi-
ces. Also the mean PFWD and MWD assessed at 
baseline was not connected with clinical outcomes 
expressed as study endpoints during the 12-month 
follow-up period. The mean Rutherford grade de-
creased significantly at the following time points 
after the PTA during the 1-year follow-up (Fig. 1A) 
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Table 1. Gene characteristics of individuals in-
cluded in the study at baseline, pharmacological 
therapy and family history. Overall group of  
patients — n = 72.
Variables Number of individuals,  
n (%)
Age [years] 66.3 ± 7.2 
65 [61.75÷72]
Gender, males 57/72 (79.1%)
Critical limb ischemia 30/70 (42.8%)
Smoking: 12/72 (16.7%)
Current 52/72 (72.2%)
Previous 64/71 (90.1%)
Whenever 31.4 ± 12.8
Years 30 [20÷40] 
18.3 ± 7.5
Cigarettes per day 20 [15÷20] 
30.0 ± 19.0
Pack years 30 [19÷40]
Hypertension 50/72 (69.4%)
Dyslipidemia 34/72 (47.2%)
Diabetes mellitus: 27/72 (37.5%)
Years of treatment 15.8 ± 7.9 
15 [10÷20]
Coronary artery disease: 26/72 (36.1%)
Myocardial infarction 10/72 (13.9%)
Kidney failure 4/72 (5.5%)
Stroke 
Family history: 6/72 (8.3%)
Hypertension 1/72 (1.4%)
Dyslipidemia 0/72 (0%)
Diabetes mellitus 2/72 (2.8%)
CAD 0/72 (0%)
Myocardial infarction 1/72 (1.4%)
Cerebral stroke 0/72 (0%)
PAD 1/72 (1.4%)
Kidney failure 0/72 (0%)
Pharmacological therapy:
Statin 7/72 (9.7%)
ARB 3/72 (4.2%)
Beta-blockers 2/72 (2.8%)
Calcium channel blockers 5/72 (6.9%)
Diuretics 3/72 (4.2%)
LMWH 1/72 (1.4%)
Acetylsalicylic acid 11/72 (15.3%)
Insulin 3/72 (4.2%)
Oral anticoagulants 2/72 (2.8%)
Thyroid hormones  
supplements
1/72 (1.4%)
Data are presented as arithmetic means ± standard deviation; me-
dian [lower÷upper quartile]. ARB — angiotensin receptor blockers; 
CAD — coronary artery disease; LMWH — low molecular weight 
heparin; PAD — peripheral artery disease
Table 2. Characteristics of culprit lesion and  
distribution of lower limb atherosclerotic  
lesions. Overall group of patients — n = 72.
Variables Number of individuals, 
n (%)
De-novo lesion: 54/70 (77.1%)
Right lower limb 27/70 (38.6%)
Left lower limb 27/70 (38.6%)
Re-intervention: 16/70 (22.8%)
Right lower limb 10/70 (14.3%)
Left lower limb 6/70 (8.6%)
Past PTA of lower  
limb arteries
30/70 (42.8%)
Past PTA of carotid arteries 1/70 (1.4%)
Localization of culprit artery:
Aorto-iliac segment (Ao-IL): 19/70 (27.1%)
One artery 13/19 (68.4%)
Two arteries 6/19 (31.6%)
Femoro-popliteal segment 
(Fem-Pop):
44/70 (62.8%)
One artery 31/44 (70.4%)
Two arteries 12/44 (27.3%)
Three arteries 1/44 (2.3%)
Below the knee artery (BTK): 24/70 (34.3%)
One artery 8/24 (33.3%)
Two arteries 9/24 (37.5%)
Three arteries 4/24 (16.7%)
Four arteries 3/24 (12.5%)
Single-segmental  
involvement:
53/70 (75.7%)
Ao-IL 17/53 (32.1%)
Fem-Pop 27/53 (50.9%)
BTK 9/53 (17%)
Dual-segmental  
involvement:
17/70 (24.3%)
Ao-IL and Fem-Pop 2/17 (11.8%)
Fem-Pop and BTK 15/17 (88.2%)
TASC Fem-pop: 44/72 (61.1%)
a 5/44 (11.4%)
b 13/44 (29.5%)
c 10/44 (22.7%)
d 16/44 (36.4%)
TASC Ao-iliac: 19/72 (26.4%)
a 6/19 (31.6%)
b 7/19 (36.8%)
c 4/19 (21%)
d 2/19 (10.5%)
Æ
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and was more significant after 12 months of follow-
up in patients with CLI at baseline compared to 
those individuals with non-CLI (p = 0.00005).  
ABI, TBI and IMT
The mean IMT value decreased significantly 
6 months after the PTA procedure compared to 
the baseline value (Table 3). The mean ABI value 
increased 1 month after PTA, however, without 
statistical significance and at following time points 
it dropped significantly, even below baseline value 
when assessed after 12  months of follow-up (Fig. 1B). 
The mean TBI value increased immediately after 
PTA (but without statistical significance) and re-
mained in favorable balance during the 12 month 
follow-up (Fig. C). The mean ABI value at baseline 
was lower in patients treated with calcium channels 
blockers (p = 0.02). It was greater in patients with 
grade A of Trans-Atlantic Inter-Society Consensus 
classification (p = 0.04) and was unexpectedly 
higher in patients with the greater mean grade 
on the Rutherford scale (p = 0.03). Also patients 
with a longer history of smoking were related with 
lower mean ABI values at baseline (r = –0.26; 
p = 0.04). ∆ABI after 6 months of follow-up was 
higher in patients with the IMT value lower than 
0.9 mm compared to those individuals with the IMT 
> 0.9 mm at baseline (p = 0.005). No relationship 
was found between IMT and clinical outcomes after 
PTA during the 12-month follow-up period.
Endothelial function
The mean FMD value increased insignificantly 
after PTA, and dropped after 6 months of follow-up 
below the baseline value (the change was statisti-
cally significant in ANOVA analysis; p = 0.04). 
The baseline mean FMD value correlated posi-
tively with ∆AI assessed at baseline and after the 
6-month follow-up period (r = 0.54; p < 0.0001). 
∆FMD was higher 1 month after PTA in patients 
with resting pain at baseline compared to those 
without it (p = 0.01). 
No relationship was found between the study 
endpoint events noticed during follow-up and the 
value of FMD at baseline or ∆FMD. 
The mean RHI value decreased directly after 
PTA and at 6 months of follow-up, however, without 
statistical significance (Table 3). The baseline val-
ues of RHI correlated positively with baseline val-
ues of systolic blood pressure (r = 0.27, p = 0.04), 
PP (r = 0.29; p = 0.03), CAP (r = 0.35, p = 
= 0.01) and CAP-HR75 (r = 0.3; p = 0.02). The 
∆RHI after 6 month follow-up was significantly 
greater in patients with past myocardial infarction 
(p = 0.008). No relationship was found between 
RHI and clinical outcomes after PTA during the 
12-month follow-up period. 
Pulse waveform analysis
The mean PP, AI, CAI, CAP, and CAP-HR75 
values decreased after PTA and continued to de-
crease at 6 month follow-up visit, however without 
statistical significance. The mean ED, SEVR, SI 
and RI values decreased insignificantly after PTA. 
They increased above the baseline value during 
the 6-month follow-up, with the exception of the 
mean SEVR value, and the trend was statisti-
cally non-significant when assessed using ANOVA 
analysis. No significant relationships were found 
between baseline values of PWA indices (except 
for SEVR) and baseline values of endothelial func-
tion parameters, markers of clinical progression 
of lower limb atherosclerosis and the frequency 
and distribution of endpoint events during the 
12-month-long follow-up period. SEVR was related 
to the endpoint events; higher values at baseline 
corresponded with significantly poorer outcomes 
expressed as study endpoint events (p = 0.04). 
Also, the decrease of the mean ED value (∆ED) 
Table 2 (cont.). Characteristics of culprit lesion 
and distribution of lower limb atherosclerotic  
lesions. Overall group of patients — n = 72.
Variables Number of individuals, 
n (%)
Graziani’s morphologic 
categorization of disease 
severity:
32/72 (44.4%)
1 1/32 (3.1%)
2a 6/32 (18.7%)
2b 2/32 (6.2%)
3 3/32 (9.4%)
4 12/32 (37.5%)
5 1/32 (3.1%)
6 6/32 (18.7%)
7 1/32 (3.1%)
Number of stenoses > 50%: 70/72 (97.2%)
1 38/70 (54.3%)
2 18/70 (25.7%)
3 11/70 (15.7%)
4 2/70 (2.8%)
5 1/70 (1.4%)
Occlusions: 10/70 (14%)
1 7/10 (70%)
2 3/10 (30%) 
PTA — percutaneous transluminal angioplasty; TASC — Trans  
Atlantic Inter-Society Consensus
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after the 1-month follow-up was significantly lower 
in males compared to females (p = 0.001). 
Follow-up analysis 
During the follow-up period lasting 386 days, 
occurrence of the study endpoints were noted in 16 
individuals. Considering those 16 individuals, the 
overall number of endpoint events was 25 and in-
cluded: 20 reinterventions, 1 myocardial infarction, 
2 deaths and 2 amputations. The Kaplan-Maier sur-
vival curve is presented in Figure 2. The probability 
of endpoint events was increased in patients with 
hypercholesterolemia at baseline (p = 0.03), indi-
viduals with CLI before PTA (p = 0.04), those with 
lower diastolic blood pressure at baseline (p = 0.03), 
in individuals with higher subendocardial viability 
ratio at baseline (p = 0.04),  those with greater 
number of pack-years before PTA (p = 0.03) and 
with lower TBI before the procedure (p = 0.02).
Clinical presentation of PAD before PTA
The current study population included 72 
patients. Out of these, 30 patients presented with 
CLI and 40 patients were without CLI (non-CLI). 
The remaining two individuals were not classified. 
A significant relationship was noticed between 
study endpoints and clinical presentation at base-
line (CLI vs. non-CLI; p = 0.04). The percentage of 
Table 3. The impact of percutaneous transluminal angioplasty (PTA) of lower limb arteries on selected 
indices at following time-points. 
At baseline After 1 month After 6 months P
Flow-mediated dilatation 4.1 ± 2.9 
3.7 [1.8÷5.8]
4.88 ± 2.9 
4.7 [2.6÷6.4]
3.4 ± 2.5 
2.9 [1.6÷4.5]
0.04
Pulse pressure 67.4 ± 12.9 
67.5 [60.2÷74.7]
66.6 ± 15.4 
65.5 [57.7÷76.5]
65.6 ± 15.6 
65 [55.5÷73]
0.8
Augmentation index 99.2 ± 17.6 
95 [85.7÷112.5]
98.4 ± 17.9 
94 [84.7÷108]
94.8 ± 14.6 
94 [85.5÷101]
0.3
Central augmentation index 156.1 ± 25.9 
150 [137.2÷174.2] 
155.8 ± 27.9 
152.3 [137.5÷167.1]
149.4 ± 20.3 
148.7 [136÷161.2]
0.28
Ejection duration 312.8 ± 26.6 
310 [290.2÷332.7]
310.4 ± 27.7 
309.5 [292÷334.5]
318.3 ± 27 
319 [302.5÷337.5]
0.32
Subendocardial viability ratio 149.9 ± 30.5 
146 [133÷167.7]
144.5 ± 28.2 
146.5 [125.5÷158.5]
148.6 ± 24.3 
147 [133.5÷162]
0.6
Central augmentation pressure 19.4 ± 9.1 
17 [13÷26]
18.7 ± 8.6 
18.5 [13.7÷22.2]
17.7 ± 8.5 
16 [12÷22]
0.57
CAP-HR75 16.3 ± 5.7 
16.5 [13÷20]
16.3 ± 5.8 
16 [13.7÷18.5]
14.2 ± 5.6** 
13[10.5÷18]
0.08
Stiffness index 19.2 ± 1.6 
20 [20÷20]
18.8 ± 2.0 
20 [18÷20]
19.2 ± 1.7 
20 [20÷20]
0.57
Reflection index 97.5 ± 5.1 
100 [100÷100]
96.2 ± 6.8 
100 [94÷100]
97.6 ± 5.5 
100 [100÷100]
0.52
Reactive hyperemia index 1.7 ± 0.7 
1.5 [1.2÷2.0]
1.7 ± 0.9 
1.4 [1.2÷1.8]
1.6 ± 0.5 
1.5 [1.3÷1.8]
0.62
Pain-free walking distance [m] 91.0 ± 142.4 
50 [20÷100]
292.3 ± 440.2* 
150 [50÷300]
394.1 ± 953.3 
100 [50÷200]
0.04
Maximal walking distance [m] 120.4 ± 150.0 
100 [30÷175]
337.5 ± 486.8* 
200 [55÷300]
535.8 ± 1244.3 
175 [100÷300]
0.02
Systolic blood pressure [mmHg] 147.3 ± 16.3 
150 [139÷158]
145.8 ± 17.6 
147 [137÷154.2]
145.1 ± 17.3 
145 [133.5÷156]
0.79
Diastolic blood pressure [mmHg] 79.8 ± 8.2 
80 [76÷84]
79.2 ± 7.2 
79 [74÷84]
9.5 ± 9.1** 
80 [75.5÷84]
0.92
Intima–media thickness [mm] 0.96 ± 0.29 
0.9 [0.77÷1.07]
– 0.93 ± 0.26 
0.86 [0.76÷0.98]
0.006
Data are presented as arithmetic means ± standard deviation; median [lower÷upper quartile]. CAP-HR75 — central augumentation pressure 
normalized for a heart rate of 75 bpm
*The value one month after PTA was significantly different from that assessed before PTA by the Wilcoxon signed-rank test.
**The value six months after PTA was significantly different from that assessed 1 month after PTA by the Wilcoxon signed-rank test.
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patients with CLI among those in which the study 
endpoints occurred was 68.7%, while in individuals 
without CLI at the baseline, the incidence of study 
endpoint events was significantly lower 35.2% 
(p = 0.04).
Discussion
Studies of brachial artery FMD have been 
reported since 1992, and today, it is the most 
widely used method in clinical research [13]. Apart 
from FMD, several other noninvasive tests for 
the assessment of endothelial function have been 
developed. In 2002, reactive hyperemia–peripheral 
arterial tonometry (RH-PAT) was reported to be 
the test for peripheral vascular endothelial func-
tion, and since then, its use has rapidly increased 
[14]. The RH-PAT technique is less operator-
dependent and uses a contralateral arm as its in-
ternal control to correct systemic changes during 
testing. FMD assesses the endothelial response 
to shear stress in the brachial artery as a result of 
hyperemia, whereas RH-PAT measures the actual 
hyperemia. However, these methods differ in target 
vasculature: the brachial artery diameter in FMD 
versus a finger arterial pulse wave in RH-PAT. The 
Framingham Heart Study reported no statistically 
significant relationships between signals obtained 
with RH-PAT and FMD, suggesting that these 
reflect distinct aspects of vascular function [15]. 
Several published studies have investigated the 
relationship between cardiovascular events and 
endothelial function, nonetheless, the number of 
studies comparing FMD and RH-PAT as predic-
tors of cardiovascular events is limited [16–18]. In 
a systematic review and meta-analysis, Matsuzawa 
Figure 1. The change in ankle-brachial index (ABI), toe-
brachial index (TBI) and Rutherford scale at following 
time points after percutaneous transluminal angioplasty 
(PTA) in comparison to baseline values; A. The change 
in the mean Rutherfordt grade value at following time 
points after PTA; B. The change in mean ABI value at 
following time points after PTA; C. The change in the 
mean TBI value at following time points after PTA
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Figure 2. Kaplan-Meier survival analysis.
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et al. [19] found that both brachial FMD and digi-
tal RHI-PAT have significant predictive value for 
future cardiovascular events after adjustment for 
other risk factors. The present analysis did not 
confirm that dependence indicating no significant 
relationship between the main indices of endothe-
lial function (FMD, IMT, RHI) and study endpoints. 
Carotid-femoral pulse wave velocity (cf-PWV) 
is another aspect addressed in this study. It is 
considered as the gold standard for estimation 
of regional arterial stiffness. Arterial stiffening 
increases systolic and pulse pressure, promotes 
left ventricular hypertrophy and dysfunction, and 
impairs capacity for myocardial perfusion [8]. It 
has been proven to be an independent predictor 
of all-cause and cardiovascular deaths in PAD 
patients [7]. It was revealed that abnormal artery 
stiffness is associated with major cardiovascular 
disease endpoints, including heart disease, stroke 
and chronic kidney disease. The present analysis 
did not confirm statistically significant dependence 
between baseline indices of artery stiffness and the 
study endpoints except for SEVR. 
Surprisingly, in this study, higher values of 
SEVR at baseline were related to poorer clinical 
outcomes during the 12-month follow-up period. 
This relation is in conflict with the current under-
standing of SEVR.
The SEVR is an index of myocardial oxygen 
supply and demand, which can be assessed non-
invasively by applanation tonometry. Low SEVR 
values indicate reduced subendocardial perfusion 
[20–22].
Low SEVR has been associated with reduced 
coronary flow reserve in patients with low ABI 
[23], microalbuminuria [24, 25], hypertension and 
cardiac autonomic neuropathy [26, 27] in patients 
with type 1 diabetes, low fitness in obesity [28, 
29] and markers of inflammation in patients with 
rheumatoid arthritis [30]. Reduced SEVR has 
been shown to predict cardiovascular mortality in 
patients with chronic kidney disease [31] and the 
combined endpoint all-cause mortality and end-
stage renal disease in patients with type 1 diabetes 
[25]. The reason for the described discrepancy 
remains unknown in our group of patients, but 
further investigation is planned on this subject. 
The higher number of study endpoints was 
also observed in patients with kidney failure, hy-
percholesterolemia, lower diastolic blood pressure 
and TBI values at baseline. 
Another finding worth mentioning is the fact 
that patients with CLI at baseline presented poorer 
clinical outcomes during the follow-up period 
compared to patients with intermittent claudica-
tion. CLI patients had significantly more episodes 
of reinterventions and study endpoints such as 
limb amputation, stroke, myocardial infarction, 
and death. 
Symptomatic PAD in the lower limb presents 
itself as either intermittent claudication or CLI. 
CLI represents the most advanced form of PAD 
and is defined as chronic ischemic resting pain, 
ulcers or gangrene attributable to arterial occlusive 
disease [32, 33]. It is well established that CLI, 
compared to patients with claudication, confers 
a substantially worse prognosis with regard to both 
limb salvage and overall survival [34]. Knowing 
that, one must be aware that CLI patients should 
be treated very differently from non-CLI patients 
in terms of time to revascularization, technique of 
procedures and even pharmacological treatment. 
These patients require faster diagnosis, frequently 
multi-stage endovascular procedures, more ag-
gressive pharmacological treatment and what is 
most important, they require a multidisciplinary 
approach.
Limitations of the study
The current study is of an observational and 
explorative nature. In the present population, it was 
necessary to first identify certain factors that could 
influence the study endpoints. Knowing these fac-
tors, the plan was to investigate them further in 
future studies. 
For that reason, this study should be treated 
as a pilot study which can explain the relatively 
low number of patients. Most of the study patients 
are still under scheduled follow-up and it will be 
possible to investigate their endothelial function 
after a longer period of time. 
Another study limitation was the fact that there 
was no coherent group of patients. The need for 
endovascular procedures was the main factor re-
sponsible for inclusion into the study. Patients were 
admitted to the clinic due to symptomatic PAD from 
different outpatient clinics. Time from diagnosis to 
the revascularization procedure was very limited, 
especially for patients with CLI. Since there was no 
control group or randomization, it was believed that 
the patients included better resemble the population.
Finally, FMD alone has some limitations. Be-
cause it is measured by ultrasound, it carries a risk 
for errors. The method is technically demanding, 
requiring specific training. Furthermore, FMD is 
very sensitive to a number of intercurrent factors 
that may influence vascular function transiently 
but may not have great importance for long-term 
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atherosclerosis risk. For example, FMD can be 
acutely lowered by an intercurrent viral illness, 
can be transiently impaired after a meal and varies 
in circadian pattern [35].
Conclusions
Baseline FMD, IMT and RHI values were not 
related to the number of study endpoints in patients 
with PAD after PTA during 12 months of follow-up. 
Among aPWA indices, higher baseline SEVR values 
corresponded with an increased number of study 
endpoints such as the number of reinterventions, 
death, myocardial infarction, amputation or stroke. 
Furthermore, the larger number of study endpoints 
was related to history of hypercholesterolemia, 
longer history of smoking, lower diastolic blood 
pressure and lower baseline TBI. Patients with 
CLI at baseline had significantly poorer treatment 
outcomes and a larger number of study endpoints 
during the 1-year follow-up period compared to 
patients with claudication.
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